Overview

* Quest Diagnostics ( DGX ) Q3 revenue rises 13.1%, beating analyst expectations

* Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

* Company raises full-year 2025 guidance, indicating confidence in continued growth

Outlook

* Company raises full-year 2025 net revenue guidance to $10.96 bln-$11.00 bln

* Quest Diagnostics ( DGX ) expects full-year adjusted EPS between $9.76 and $9.84

* Company anticipates cash from operations of approximately $1.8 bln for 2025

Result Drivers

* ORGANIC AND ACQUISITION GROWTH - Revenue growth driven by 6.8% organic growth and contributions from acquisitions

* COREWELL JOINT VENTURE - Agreement with Corewell Health to establish a lab services joint venture in Michigan

* CONSUMER CHANNEL EXPANSION - Growth in consumer channel as Quest builds presence as preferred lab engine inside top health and wellness brands

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $2.81 $2.73

Revenue bln bln (13

Analysts

)

Q3 Beat $2.60 $2.50

Adjusted (15

EPS Analysts

)

Q3 EPS $2.16

Q3 Net $245 mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Quest Diagnostics Inc ( DGX ) is $190.50, about 0% above its October 20 closing price of $190.41

* The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)